HRP20020701B1 - A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR - Google Patents

A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Info

Publication number
HRP20020701B1
HRP20020701B1 HR20020701A HRP20020701A HRP20020701B1 HR P20020701 B1 HRP20020701 B1 HR P20020701B1 HR 20020701 A HR20020701 A HR 20020701A HR P20020701 A HRP20020701 A HR P20020701A HR P20020701 B1 HRP20020701 B1 HR P20020701B1
Authority
HR
Croatia
Prior art keywords
crystalline form
pyrrolo
pyrimidin
dihydro
benzoyl
Prior art date
Application number
HR20020701A
Other languages
English (en)
Croatian (hr)
Inventor
Christopher Chelius Erik
Marie Reutzel-Edens Susan
Van Den Berghe Snorek Sharon
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20020701A2 publication Critical patent/HRP20020701A2/hr
Publication of HRP20020701B1 publication Critical patent/HRP20020701B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HR20020701A 2000-02-25 2002-08-26 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR HRP20020701B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (fr) 2000-02-25 2001-02-12 Nouvelle forme cristalline de n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-acide glutamique et procede correspondant

Publications (2)

Publication Number Publication Date
HRP20020701A2 HRP20020701A2 (en) 2003-12-31
HRP20020701B1 true HRP20020701B1 (en) 2011-02-28

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020701A HRP20020701B1 (en) 2000-02-25 2002-08-26 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Country Status (36)

Country Link
US (1) US7138521B2 (fr)
EP (1) EP1259513B1 (fr)
JP (1) JP4846158B2 (fr)
KR (1) KR100744917B1 (fr)
CN (1) CN1183135C (fr)
AR (1) AR029471A1 (fr)
AT (1) ATE249462T1 (fr)
AU (1) AU777047B2 (fr)
BR (1) BR0108604A (fr)
CA (1) CA2400155C (fr)
CO (1) CO5261585A1 (fr)
CZ (1) CZ303772B6 (fr)
DE (1) DE60100750T2 (fr)
DK (1) DK1259513T3 (fr)
DZ (1) DZ3283A1 (fr)
EA (1) EA004684B1 (fr)
EG (1) EG24073A (fr)
ES (1) ES2206403T3 (fr)
HK (1) HK1051856A1 (fr)
HR (1) HRP20020701B1 (fr)
HU (1) HU229704B1 (fr)
IL (2) IL150480A0 (fr)
MX (1) MXPA02008242A (fr)
MY (1) MY124784A (fr)
NO (1) NO323422B1 (fr)
NZ (1) NZ519796A (fr)
PE (1) PE20011082A1 (fr)
PL (1) PL208061B1 (fr)
PT (1) PT1259513E (fr)
SI (1) SI1259513T1 (fr)
SK (1) SK287375B6 (fr)
SV (1) SV2002000321A (fr)
TW (1) TWI237024B (fr)
UA (1) UA72791C2 (fr)
WO (1) WO2001062760A2 (fr)
ZA (1) ZA200205265B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
CA2636596A1 (fr) * 2005-11-04 2007-05-18 James Pluda Traitement anticancereux au saha et au pemetrexed
EP1942907A2 (fr) * 2005-11-04 2008-07-16 Merck and Co., Inc. Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer
US7994180B2 (en) * 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
EP2305681A1 (fr) * 2006-08-14 2011-04-06 Sicor, Inc. Forme cristalline de diacide de pemetrexed et son procédé de préparation
JP2008543975A (ja) 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
JP2010509221A (ja) * 2006-11-03 2010-03-25 ユニバーシテイ・オブ・メリーランド，ボルテイモア 多発性骨髄腫を治療するためにｓａｈａおよびボルテゾミブを使用する方法
JP2010523589A (ja) * 2007-04-03 2010-07-15 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドの固体形
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010028105A2 (fr) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Disodium de pemetrexed amorphe
WO2010030598A2 (fr) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques comprenant du pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
ES2639639T3 (es) 2011-03-25 2017-10-27 Scinopharm Taiwan, Ltd. Proceso para la producción de pemetrexed disódico
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (fr) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Procédé de préparation de dipotassium de pemetrexed cristallin
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
EP2983649A1 (fr) 2013-04-12 2016-02-17 Actavis Group PCT ehf Formulation de pemetrexed
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
JP2016527227A (ja) 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
EP3040074B1 (fr) 2013-10-03 2018-07-25 Fujifilm Corporation Préparation pharmaceutique d'injection, et procédé de fabrication de celle-ci
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA3015436C (fr) 2014-10-30 2020-07-21 Scinopharm Taiwan, Ltd. Formes cristallines de diacide de pemetrexed et procedes de fabrication connexes
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
AU2018349426B2 (en) * 2017-10-10 2024-01-18 Sun Pharmaceutical Industries Limited Intravenous infusion dosage form for pemetrexed

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (fr) * 1996-08-30 1998-03-05 Eli Lilly And Company Antifoliques non classiques de pyrrolo[2,3-d]pyrimidine
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
UA53742C2 (uk) * 1997-09-26 2003-02-17 Елі Ліллі Енд Компані Спосіб одержання альдегідів, які використовують при синтезі сполук, цінних як антифолати
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
NZ519796A (en) 2003-01-31
NO20023974D0 (no) 2002-08-21
UA72791C2 (uk) 2005-04-15
TWI237024B (en) 2005-08-01
SK11862002A3 (sk) 2003-01-09
AR029471A1 (es) 2003-07-02
US20030216416A1 (en) 2003-11-20
WO2001062760A3 (fr) 2001-12-06
DE60100750T2 (de) 2004-07-29
JP4846158B2 (ja) 2011-12-28
NO20023974L (no) 2002-08-21
CN1183135C (zh) 2005-01-05
CA2400155A1 (fr) 2001-08-30
EG24073A (en) 2008-05-11
SI1259513T1 (en) 2003-12-31
HUP0204232A3 (en) 2006-01-30
MY124784A (en) 2006-07-31
PE20011082A1 (es) 2001-10-22
EA200200905A1 (ru) 2003-02-27
HU229704B1 (en) 2014-05-28
CZ20022875A3 (cs) 2003-02-12
SK287375B6 (sk) 2010-08-09
DK1259513T3 (da) 2004-01-12
HRP20020701A2 (en) 2003-12-31
EP1259513A2 (fr) 2002-11-27
ES2206403T3 (es) 2004-05-16
AU777047B2 (en) 2004-09-30
US7138521B2 (en) 2006-11-21
KR20020075449A (ko) 2002-10-04
ATE249462T1 (de) 2003-09-15
DE60100750D1 (de) 2003-10-16
WO2001062760A2 (fr) 2001-08-30
NO323422B1 (no) 2007-04-30
SV2002000321A (es) 2002-07-16
EA004684B1 (ru) 2004-06-24
ZA200205265B (en) 2003-11-11
EP1259513B1 (fr) 2003-09-10
AU3445101A (en) 2001-09-03
BR0108604A (pt) 2002-11-19
PT1259513E (pt) 2004-02-27
DZ3283A1 (fr) 2001-08-30
IL150480A (en) 2007-12-03
PL356423A1 (en) 2004-06-28
JP2003530321A (ja) 2003-10-14
CN1406238A (zh) 2003-03-26
MXPA02008242A (es) 2002-11-29
IL150480A0 (en) 2002-12-01
HUP0204232A2 (hu) 2003-04-28
KR100744917B1 (ko) 2007-08-01
CA2400155C (fr) 2009-09-15
CZ303772B6 (cs) 2013-05-02
CO5261585A1 (es) 2003-03-31
PL208061B1 (pl) 2011-03-31
HK1051856A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
HRP20020701B1 (en) A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
MY126862A (en) Purine derivatives inhibitors of tyrosine protein kinase syk
CY1113322T1 (el) 3-{(3R,4R)-4-ΜΕΘΥΛ-3-[ΜΕΘΥΛ-(7Η-ΠΥΡΡΟΛΟ[2,3-d]ΠΥΡΙΜΙΔΙΝ-4-ΥΛ)-ΑΜΙΝΟ]-ΠΙΠΕΡΙΔΙΝΥΛ}-3-ΟΞΟ-ΠΡΟΠΙΟΝΙΤΡΙΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΩΝ ΠΡΩΤΕΪΝΗΣ
GR3033449T3 (en) Piperazine derivatives as 5ht1a antagonists
HRP20090335T1 (en) CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT
MY140674A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
NO995006D0 (no) Nye forbindelser
IL118889A0 (en) N-(aroyl) glycine hydroxamic acid derivatives and related compounds
CO4700469A1 (es) 3-[4-(4(4-cianofenil)-1-piperazinanil)butil]-5]ciannoindol y su proceso de obtencion .
EP1140900A4 (fr) Composes pyrazole et utilisation de tels composes
EA199700106A1 (ru) Замещенные 2-фенилпиридины в качестве гербицидов
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
ITMI20042231A1 (it) Cefdinir sale d'ammonio in forma cristallina
EP1325918A4 (fr) Inhibiteurs de l'apoptose des cellules du muscle cardiaque et agents therapeutiques/prophylactiques contre les maladies cardiaques
ITUD20020014A1 (it) Procedimento per il rivestimento di oggetti per mezzo di elettrodeposizione ed oggetti cosi' ottenuti
TH78405S (th) ลวดลายจาน
TH25918S1 (th) ลวดลายจาน
TH18805S1 (th) นาฬิกาตั้งโต๊ะ
TH18653S1 (th) นาฬิกาตั้งโต๊ะ
TH22714S1 (th) กล่อง
TH24518S1 (th) นาฬิกาแขวน
TH18656S1 (th) นาฬิกาแขวน
TH23234S1 (th) ครอบโค้งสันตะเข้
TH66737S (th) ครอบโค้งสันตะเข้
TH63039S (th) จี้

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180208

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20190212